BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32027921)

  • 1. Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs.
    Mills BJ; Kruger T; Bruncko M; Zhang X; Jameel F
    J Pharm Sci; 2020 May; 109(5):1662-1672. PubMed ID: 32027921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates.
    Johann F; Wöll S; Winzer M; Gieseler H
    J Pharm Sci; 2024 May; 113(5):1265-1274. PubMed ID: 38070776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
    Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
    Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering.
    Law-Hine D; Rudiuk S; Bonestebe A; Ienco R; Huille S; Tribet C
    Mol Pharm; 2019 Dec; 16(12):4902-4912. PubMed ID: 31618040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
    Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
    J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG.
    Shao S; Tsai MH; Lu J; Yu T; Jin J; Xiao D; Jiang H; Han M; Wang M; Wang J
    Bioorg Med Chem Lett; 2018 May; 28(8):1363-1370. PubMed ID: 29559276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconjugation and Linker-like Labeling (PADDLL) Method.
    Yang X; Seol H; Lin W; Xu X; Shen B; Qiu H; Li N
    Anal Chem; 2021 Jul; 93(27):9549-9558. PubMed ID: 34196532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates.
    Gandhi AV; Arlotta KJ; Chen HN; Owen SC; Carpenter JF
    J Pharm Sci; 2018 Jul; 107(7):1858-1869. PubMed ID: 29626535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing localized conformational stability of antibody-drug conjugate by protein conformation assay.
    Fu C; Zhang Z; Zhou S; Pritts WA; Zhang Q
    J Pharm Biomed Anal; 2020 Feb; 179():113020. PubMed ID: 31835127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads.
    Pysz I; Jackson PJM; Barlow DJ; Rahman KM; Thurston DE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1146():122075. PubMed ID: 32361467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
    Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
    J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation.
    Guo J; Kumar S; Chipley M; Marcq O; Gupta D; Jin Z; Tomar DS; Swabowski C; Smith J; Starkey JA; Singh SK
    Bioconjug Chem; 2016 Mar; 27(3):604-15. PubMed ID: 26829368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural characterization of a monomethylauristatin-E based ADC that contains 8 drugs conjugated at interchain cysteine residues.
    Chiu D; Pan L; Fay L; Eakin C; Valliere-Douglass J
    J Pharm Biomed Anal; 2021 Oct; 205():114309. PubMed ID: 34403866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.
    Tumey LN; Li F; Rago B; Han X; Loganzo F; Musto S; Graziani EI; Puthenveetil S; Casavant J; Marquette K; Clark T; Bikker J; Bennett EM; Barletta F; Piche-Nicholas N; Tam A; O'Donnell CJ; Gerber HP; Tchistiakova L
    AAPS J; 2017 Jul; 19(4):1123-1135. PubMed ID: 28439809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates.
    Chen T; Su D; Gruenhagen J; Gu C; Li Y; Yehl P; Chetwyn NP; Medley CD
    J Pharm Biomed Anal; 2016 Jan; 117():304-10. PubMed ID: 26406314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical Methods for Characterization of Antibody-Drug Conjugates.
    Mudhivarthi VK; Guo J
    Methods Mol Biol; 2020; 2078():313-327. PubMed ID: 31643067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering.
    Benjamin SR; Jackson CP; Fang S; Carlson DP; Guo Z; Tumey LN
    Mol Pharm; 2019 Jun; 16(6):2795-2807. PubMed ID: 31067063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.